Disease · MONDO_0005235
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Active Monitoring (ACTM) vs Arm B: Daratumumab SC: deaths from any cause | 26 of 196 | 15 of 194 | 390 | NCT03301220 | Trial comparisons |
| Arm A: Active Monitoring (ACTM) vs Arm B: Daratumumab SC: serious adverse events | 38 of 196 | 56 of 193 | 389 | NCT03301220 | Trial comparisons |
| Siltuximab vs Placebo: deaths from any cause | 3 of 43 | 4 of 42 | 85 | NCT01484275 | Trial comparisons |
| Siltuximab vs Placebo: serious adverse events | 13 of 43 | 13 of 42 | 85 | NCT01484275 | Trial comparisons |
| Arm I: Thal/ZLD vs Arm II: ZLD: Number of Participants With Severe (Grade 3, 4 or 5) Adverse Events | 17 of 35 | 13 of 33 | 68 | NCT00432458 | Trial comparisons |
Arm I: Thal/ZLD vs Arm II: ZLD: Number of Participants With a Confirmed Response (Complete Response [CR], Very Good Partial Response [VGPR] or Partial Response [PR]) on Two Consecutive Evaluations at Least 2 Weeks Apart in the First 12 Months of Treatment | 13 of 35 | 0 of 33 | 68 | NCT00432458 | Trial comparisons |
| Arm I: Thal/ZLD vs Arm II: ZLD: 12-month Progression-free Survival (PFS) | 30 of 35 | 18 of 33 | 68 | NCT00432458 | Trial comparisons |
| Arm I: Thal/ZLD vs Arm II: ZLD: serious adverse events | 3 of 35 | 1 of 33 | 68 | NCT00432458 | Trial comparisons |
| Elotuzumab(E) : 10 mg/kg/Dose vs Elotuzumab(E) : 20 mg/kg/Dose: serious adverse events | 7 of 16 | 8 of 15 | 31 | NCT01441973 | Trial comparisons |
| Cohort B (Lenalidomide, Dexamethasone) vs Cohort C (Lenalidomide, Dexamethasone, Pomalidomide): deaths from any cause | 0 of 5 | 0 of 11 | 16 | NCT05288062 | Trial comparisons |
| Cohort B (Lenalidomide, Dexamethasone) vs Cohort C (Lenalidomide, Dexamethasone, Pomalidomide): serious adverse events | 0 of 5 | 2 of 11 | 16 | NCT05288062 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005235/comparisons